Gyre Therapeutics acquires Cullgen

Gyre Therapeutics agreed to acquire Cullgen. Reported deal value: $300M. Status: Pending. Sector: biotechnology. Target headquarters context: San Diego, California, United States.

This page summarizes publicly available information about the transaction as of 2026-03-02. Figures and status may change as filings and press coverage update.

Agreement and Plan of Merger and Reorganization On March 2, 2026, Gyre Therapeutics , Inc., a Delaware corporation , entered into an Agreement and Plan of Merger and Reorganization with Cullgen Inc., a Delaware corporation , and Helix Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company , pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement , Merger Sub will merge with and into Cullgen , with Cullgen continuing as a wholly owned subsidiary of the Company and the surviving corporat...